MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
04 MAR 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA Patent covers paired Cas9 nickase technology to advance gene therapy and research, reduce off-target effects Marks MilliporeSigma’s 13th CRISPR patent overall Actively licensing CRISPR-related patents to interested parties Burlington, Massachusetts, March 4, 2019 – MilliporeSigma, a leader in genome editing, today announced that the Canadian Patent Office has allowed... Read more